Poseida Therapeutics Added to NASDAQ Biotechnology Index

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ — Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (Nasdaq: NBI). Addition to the NBI will become effective prior to market open on Monday, December 21, 2020.